Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

HER-family ligands promote acquired resistance to trastuzumab in gastric cancer.

Sampera A, Sánchez-Martín FJ, Arpí O, Visa L, Iglesias M, Menéndez S, Gaye É, Dalmases A, Clavé S, Gelabert-Baldrich M, Poulsen TT, Kragh M, Bellosillo B, Albanell J, Rovira A, Montagut C.

Mol Cancer Ther. 2019 Sep 4. pii: molcanther.0455.2019. doi: 10.1158/1535-7163.MCT-19-0455. [Epub ahead of print]

PMID:
31484705
2.

Molecular analysis of peripheral lung adenocarcinoma in brush cytology obtained by EBUS plus fluoroscopy-guided bronchoscopy.

Sánchez-Font A, Chalela R, Martín-Ontiyuelo C, Albero-González R, Dalmases A, Longarón R, Alonso-Espinaco V, Curull V, Bellosillo B, Pijuan L.

Cancer Cytopathol. 2018 Oct;126(10):860-871. doi: 10.1002/cncy.22053. Epub 2018 Oct 6.

3.

Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma.

Taus Á, Camacho L, Rocha P, Hardy-Werbin M, Pijuan L, Piquer G, López E, Dalmases A, Longarón R, Clavé S, Salido M, Albanell J, Bellosillo B, Arriola E.

Clin Lung Cancer. 2018 Sep;19(5):387-394.e2. doi: 10.1016/j.cllc.2018.03.015. Epub 2018 Mar 23.

PMID:
29656868
4.

Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients.

Vidal J, Muinelo L, Dalmases A, Jones F, Edelstein D, Iglesias M, Orrillo M, Abalo A, Rodríguez C, Brozos E, Vidal Y, Candamio S, Vázquez F, Ruiz J, Guix M, Visa L, Sikri V, Albanell J, Bellosillo B, López R, Montagut C.

Ann Oncol. 2017 Jun 1;28(6):1325-1332. doi: 10.1093/annonc/mdx125.

5.

Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.

Brammeld JS, Petljak M, Martincorena I, Williams SP, Alonso LG, Dalmases A, Bellosillo B, Robles-Espinoza CD, Price S, Barthorpe S, Tarpey P, Alifrangis C, Bignell G, Vidal J, Young J, Stebbings L, Beal K, Stratton MR, Saez-Rodriguez J, Garnett M, Montagut C, Iorio F, McDermott U.

Genome Res. 2017 Apr;27(4):613-625. doi: 10.1101/gr.213546.116. Epub 2017 Feb 8.

6.

Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.

Casadevall D, Vidal J, Gallardo F, Zuccarino F, Arumí-Uría M, Dalmases A, Bellosillo B, Montagut C.

J Med Case Rep. 2016 Jun 2;10(1):158. doi: 10.1186/s13256-016-0953-0.

7.

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.

Sánchez-Martín FJ, Bellosillo B, Gelabert-Baldrich M, Dalmases A, Cañadas I, Vidal J, Martinez A, Argilés G, Siravegna G, Arena S, Koefoed K, Visa L, Arpí O, Horak ID, Iglesias M, Stroh C, Kragh M, Rovira A, Albanell J, Tabernero J, Bardelli A, Montagut C.

Clin Cancer Res. 2016 Jul 1;22(13):3260-7. doi: 10.1158/1078-0432.CCR-15-2400. Epub 2016 Feb 17.

8.

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

Arena S, Bellosillo B, Siravegna G, Martínez A, Cañadas I, Lazzari L, Ferruz N, Russo M, Misale S, González I, Iglesias M, Gavilan E, Corti G, Hobor S, Crisafulli G, Salido M, Sánchez J, Dalmases A, Bellmunt J, De Fabritiis G, Rovira A, Di Nicolantonio F, Albanell J, Bardelli A, Montagut C.

Clin Cancer Res. 2015 May 1;21(9):2157-66. doi: 10.1158/1078-0432.CCR-14-2821. Epub 2015 Jan 26.

9.

Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.

García-Parra J, Dalmases A, Morancho B, Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, Eroles P, Servitja S, Tusquets I, Yelamos J, Lluch A, Arribas J, Rojo F, Rovira A, Albanell J.

Eur J Cancer. 2014 Oct;50(15):2725-34. doi: 10.1016/j.ejca.2014.07.004. Epub 2014 Aug 12.

PMID:
25128455
10.

Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancer.

Dalmases A, González I, Menendez S, Arpí O, Corominas JM, Servitja S, Tusquets I, Chamizo C, Rincón R, Espinosa L, Bigas A, Eroles P, Furriol J, Lluch A, Rovira A, Albanell J, Rojo F.

Oncotarget. 2014 Jan 15;5(1):196-210.

11.

[The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].

Dalmases A, Rojo F, Rovira A, Albanell J.

Med Clin (Barc). 2013 Aug 17;141(4):176-80. doi: 10.1016/j.medcli.2013.04.008. Epub 2013 Jun 27. Review. Spanish. No abstract available.

PMID:
23809407
12.

Inhibition of specific NF-κB activity contributes to the tumor suppressor function of 14-3-3σ in breast cancer.

Inglés-Esteve J, Morales M, Dalmases A, Garcia-Carbonell R, Jené-Sanz A, López-Bigas N, Iglesias M, Ruiz-Herguido C, Rovira A, Rojo F, Albanell J, Gomis RR, Bigas A, Espinosa L.

PLoS One. 2012;7(5):e38347. doi: 10.1371/journal.pone.0038347. Epub 2012 May 31.

13.

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.

Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Seshagiri S, Serrano S, Himmelbauer H, Bellmunt J, Rovira A, Settleman J, Bosch F, Albanell J.

Nat Med. 2012 Jan 22;18(2):221-3. doi: 10.1038/nm.2609. Erratum in: Nat Med. 2012 Sep;18(9):1445. Somasekar, Seshagiri [corrected to Seshagiri, Somasekar].

PMID:
22270724
14.

Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.

Montagut C, Iglesias M, Arumi M, Bellosillo B, Gallen M, Martinez-Fernandez A, Martinez-Aviles L, Cañadas I, Dalmases A, Moragon E, Lema L, Serrano S, Rovira A, Rojo F, Bellmunt J, Albanell J.

Br J Cancer. 2010 Mar 30;102(7):1137-44. doi: 10.1038/sj.bjc.6605612. Epub 2010 Mar 16.

15.

Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin.

Rojo F, González-Navarrete I, Bragado R, Dalmases A, Menéndez S, Cortes-Sempere M, Suárez C, Oliva C, Servitja S, Rodriguez-Fanjul V, Sánchez-Pérez I, Campas C, Corominas JM, Tusquets I, Bellosillo B, Serrano S, Perona R, Rovira A, Albanell J.

Clin Cancer Res. 2009 May 15;15(10):3530-9. doi: 10.1158/1078-0432.CCR-08-2070. Epub 2009 May 5.

16.

Pharmacodynamics: biological activity of targeted therapies in clinical trials.

Rojo F, Dalmases A, Corominas JM, Albanell J.

Clin Transl Oncol. 2007 Oct;9(10):634-44. Review.

PMID:
17974524
17.

Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin.

Tapia MA, González-Navarrete I, Dalmases A, Bosch M, Rodriguez-Fanjul V, Rolfe M, Ross JS, Mezquita J, Mezquita C, Bachs O, Gascón P, Rojo F, Perona R, Rovira A, Albanell J.

Cell Cycle. 2007 Sep 15;6(18):2284-92. Epub 2007 Jul 10.

18.

mTOR signalling in human cancer.

Albanell J, Dalmases A, Rovira A, Rojo F.

Clin Transl Oncol. 2007 Aug;9(8):484-93. Review.

PMID:
17720651

Supplemental Content

Loading ...
Support Center